Is GHRP-6 FDA-approved?

No. GHRP-6 isn't FDA-approved: Drugs@FDA lists no application with it, and FDA puts it on its Category 2 list of bulk substances for compounding that may present significant safety risks.

Checked 1 Nov 2026. The sources are below.

GHRP-6

Also: Growth Hormone-Releasing Peptide-6, growth hormone releasing hexapeptide, SK&F 110679, Hexapeptide-2

Status label in the Peptimes Library
Compounding Restricted
Routes in Peptimes
Subcutaneous
Updated
1 Nov 2026

US regulatory status

  • FDA status

    Not FDA-Approved. Drugs@FDA lists no application with GHRP-6 as an active ingredient.

    Source: Drugs@FDA, checked 1 Nov 2026

  • FDA status

    On FDA's Category 2 list: FDA lists growth hormone releasing peptide-6 (GHRP-6) among bulk drug substances for compounding that may present significant safety risks, under its interim policy for outsourcing facilities (503B), added 29 Sep 2023.

    Source: FDA, checked 1 Nov 2026

How to track it in Peptimes

Add GHRP-6 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Compounding Restricted”, the app’s label for compounds on FDA’s Category 2 list. Category 2 is FDA’s list of bulk drug substances for compounding that may present significant safety risks; it is not an approval.

  • Logging: the amount you took and how you feel.
  • Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
  • Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.

Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell GHRP-6 or any other compound.

More sources

Coming soon to the App Store

Coming soon to Google Play

See planned pricing